Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 2.53B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -99.68M |
| Shares Out | 37.43M |
| EPS (ttm) | -2.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 21 |
| Last Price | $69.31 |
| Previous Close | $67.35 |
| Change ($) | 1.96 |
| Change (%) | 2.90% |
| Day's Open | 66.93 |
| Day's Range | 65.85 - 69.74 |
| Day's Volume | 174,904 |
| 52-Week Range | 50.05 - 90.00 |
The stock price of Axsome Therapeutics, a biopharmaceutical company focused on developing novel therapies for central nervous system conditions, has seen a 13% rise over the last twenty-one trading sess...
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission is cu...
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Company to host conference call today at 8:00 AM Eastern
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month, by ra...
The stocks of Novavax and Axsome Therapeutics are soaring. Here's why.
Their stocks have collapsed. But they could still be huge winners.
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...
The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate.
The first new treatment for millions of Americans with major depressive disorder could become available this summer.
Axsome Therapeutics snagged a speedy review from the Food and Drug Administration for its depression treatment, known as AXS-05, on Monday, leading Axsome stock to gap higher. The post Axsome Stock Jump...
AXSM stock is gaining on Monday after the FDA granted its new drug application priority review. Here's what you should know now.
Under Priority review status, the FDA has accepted Axsome Therapeutics Inc's (NASDAQ: AXSM) marketing application for AXS-05 for major depressive disorder (MDD). The target action date is set at August 22.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
The upstart biotech is filing two new drug applications in 2021, and has several more on the way.
Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,...
This company presents much more attractive prospects than the cryptocurrency.
While it's already made some people rich, Axsome Therapeutics is just getting started.
Take a look at a few trending biotech stocks and decide if this is something you want to invest in.
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.
ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation
Over 21,000 migraine attacks treated with AXS-07
The second half of 2020 has been pretty dull in terms of AXSM trading relative to the first half. Several positive readouts in H2'20 provided only a modest boost but set the stage for a H1'21 readout of...
68 % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
R apid and substantial i mprovement in depressive symptoms achieved by 44 % of patients at 2 weeks, 67 % at 6 weeks (MADRS response) , and sustained with long-term treatment
R apid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response) , and sustained over 12 months
Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript
NEW YORK & PLEASANTON, Calif.--(BUSINESS WIRE)-- #digitalengagement--Axsome and Veeva announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC™) platform.
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders,...
Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time
Axsome has an excellent pipeline of late stage CNS candidates. The total market opportunity of all 4 assets is nearly $8bn.
When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades appeared fir...
The Recent Sell-Off In Axsome Creates A Good Opportunity
Today, we revisit Axsome Therapeutics for an in-depth analysis.
An analyst doesn't think very highly of Axsome's prospects.
Non-dilutive committed capital extends cash runway into at least 2024
S ignificantly faster time to pain relief as compared to rizatriptan (p
Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 ... [Read more...]
| Industry Biotechnology | IPO Date Nov 19, 2015 |
| CEO Herriot Tabuteau | Employees 70 |
| Stock Exchange NASDAQ | Ticker Symbol AXSM |
Analyst Forecasts
According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is 140.21, which is an increase of 102.31% from the latest price.